NewcelX NCEL-101 / IsletRx
NewcelX
A pre-IND stem-cell-derived islet replacement program for insulin-dependent T1D, with NewcelX exploring combination immune protection using Eledon's anti-CD40L antibody tegoprubart.
The scorecard
No human data yet; the program is pre-IND and has not entered a first-in-human trial.[2]
Durability is a stated goal, especially with tegoprubart immune modulation, but remains preclinical.[3]
Combination with anti-CD40L tegoprubart aims to support graft survival, but this is not immunosuppression-free proof.[3]
As an islet replacement therapy it will require transplantation or infusion; final route is not yet publicly established.[1]
Potentially scalable if it reaches clinic, but eligibility is undefined before the IND and first protocol.[2]
The full picture
NewcelX is not yet a clinical competitor to Vertex or Sana, but it is now visible enough to track. The May 2026 pre-IND package and Eledon collaboration put NCEL-101 on the horizon for first-in-human testing. The scientific bet is familiar: manufacture insulin-producing islet cells, then pair them with immune modulation strong enough to protect the graft without the worst transplant-drug burden.
Coming soon
ETA · Pre-IND package submitted; first-in-human trial not yet open
Sources
- [1]NewcelX pipeline: IsletRx / NCEL-101 for type 1 diabetes · manufacturer
- [2]NewcelX submits pre-IND package to FDA for NCEL-101 for type 1 diabetes · manufacturer · 2026-05-27
- [3]NewcelX announces strategic collaboration with Eledon to advance NCEL-101 program for type 1 diabetes · manufacturer · 2026-03-09